Consequently, the PD-1-blocking monoclonal antibodies pembrolizumab and nivolumab showed promising anti-cancer effects with tolerable adverse effects in [3] and are currently being used to treat non-small cell lung cancer (NSCLC), melanoma, bladder and colorectal cancer, and Hodgkin lymphoma, among others [4,5]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.